Figure 1

TAM combined with CXB additively inhibits survival of breast cancer cells. In vitro cell viability assay of MCF7, MDA-MB-231, T-47D, MDA-MB-468, NIH/3T3 and HaCaT cells treated with (A) TAM, (B) CXB, or (C) both (0–5 μM TAM plus 30 μM CXB) for 48 h. Data are means ± SE of three independent experiments p < 0.05. (D) Representative histogram of MCF7 cells (top row) and MDA-MB-231 (bottom row) cells and their cell-cycle distribution after 48 h of treatment, as determined by flow cytometry followed by staining of cells with PI. T + C, TAM plus CXB; UT, untreated.